Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vito Lorusso

Showing results (81-90 of 218) with videos related to

Pageof 22
Sort By:
Asian Journal of Urology|November 13, 2024
Robot-assisted radical cystectomy with neobladder diversion in females: Safety profile and functional outcomesAndrea Pacchetti, Alberto Caviglia, Vito Lorusso, et al.
Turkish Journal of Urology|October 28, 2020
Repair of a rectovesical fistula following laparoscopic radical prostatectomy with Martius fat pad flap interposition: a proposal of a new techniqueGiacomo Piero Incarbone, Franco Palmisano, Vito Lorusso, et al.
Cancer|November 17, 2006
Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II studySergio Palmeri, Vito Lorusso, Laura Palmeri, et al.
Medical Oncology (Northwood, London, England)|April 25, 2013
Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?Nicola Calvani, Franco Morelli, Vincenzo Chiuri, et al.
Magma (New York, N.Y.)|March 5, 2008
Tumor microvasculature observed using different contrast agents: a comparison between Gd-DTPA-Albumin and B-22956/1 in an experimental model of mammary carcinomaFederico Boschi, Pasquina Marzola, Marco Sandri, et al.
Breast (Edinburgh, Scotland)|February 20, 2010
Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studiesVito Lorusso, Saverio Cinieri, Marianna Giampaglia, et al.
Current Drug Metabolism|July 27, 2011
Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patientsAntonio Gnoni, Antonio Russo, Nicola Silvestris, et al.
Expert Opinion on Therapeutic Targets|July 10, 2015
MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitorsRosamaria Pinto, Sabino Strippoli, Simona De Summa, et al.
Cancer|April 28, 2009
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinomaFabio Calabrò, Vito Lorusso, Gerardo Rosati, et al.
Cancer Letters|July 29, 2011
Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cellsDaniele Vergara, Concetta Maria Valente, Andrea Tinelli, et al.
Pageof 22

Showing results (81-90 of 218) with videos related to

Sort By:
Pageof 22
Asian Journal of Urology|November 13, 2024
Robot-assisted radical cystectomy with neobladder diversion in females: Safety profile and functional outcomesAndrea Pacchetti, Alberto Caviglia, Vito Lorusso, et al.
Turkish Journal of Urology|October 28, 2020
Repair of a rectovesical fistula following laparoscopic radical prostatectomy with Martius fat pad flap interposition: a proposal of a new techniqueGiacomo Piero Incarbone, Franco Palmisano, Vito Lorusso, et al.
Cancer|November 17, 2006
Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II studySergio Palmeri, Vito Lorusso, Laura Palmeri, et al.
Medical Oncology (Northwood, London, England)|April 25, 2013
Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?Nicola Calvani, Franco Morelli, Vincenzo Chiuri, et al.
Magma (New York, N.Y.)|March 5, 2008
Tumor microvasculature observed using different contrast agents: a comparison between Gd-DTPA-Albumin and B-22956/1 in an experimental model of mammary carcinomaFederico Boschi, Pasquina Marzola, Marco Sandri, et al.
Breast (Edinburgh, Scotland)|February 20, 2010
Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studiesVito Lorusso, Saverio Cinieri, Marianna Giampaglia, et al.
Current Drug Metabolism|July 27, 2011
Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patientsAntonio Gnoni, Antonio Russo, Nicola Silvestris, et al.
Expert Opinion on Therapeutic Targets|July 10, 2015
MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitorsRosamaria Pinto, Sabino Strippoli, Simona De Summa, et al.
Cancer|April 28, 2009
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinomaFabio Calabrò, Vito Lorusso, Gerardo Rosati, et al.
Cancer Letters|July 29, 2011
Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cellsDaniele Vergara, Concetta Maria Valente, Andrea Tinelli, et al.
Pageof 22